Alta Partners

Portfolio Co Investors 2026 for Alta Partners: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Alta Partners accounts for 19 tracked companies with verified cap-table data, 19 of which disclose round sizes totalling $2.7B. The median disclosed raise is $85M, and the largest is EGenesis at $481M, ahead of BridgeHealth ($450M) and DispatchHealth ($417M).

The names that recur most often on these co-invested cap tables are Alta Partners (19 companies), Longwood Fund (4 companies), General Catalyst (3 companies), Domain Associates (3 companies), Lux Capital (2 companies), Leaps by Bayer (2 companies). By latest disclosed round, the market skews Series A (7), Series D (5), Series B (5), Series E (1).

Best funded Alta Partners companies

  1. EGenesis — $481M (latest: Series D)
  2. BridgeHealth — $450M (latest: Series D)
  3. DispatchHealth — $417M (latest: Series D)
  4. Trevena — $174M
  5. Variant Bio — $130M (latest: Series B)
  6. Harbor Health — $130M (latest: Series D)
  7. ImmuneID — $113M (latest: Series A)
  8. MBrace Therapeutics — $110M (latest: Series B)
  9. aTyr Pharma — $90M (latest: Series E)
  10. Lassen Therapeutics — $85M (latest: Series B)
  11. Qihan Biotech — $75M (latest: Series B)
  12. DEM BioPharma — $70M (latest: Series A)
  13. Progentos Therapeutics — $65M (latest: Series A)
  14. CuraSen Therapeutics — $60M (latest: Series B)
  15. Cara Therapeutics — $56M (latest: Series D)

ALTA Partners — related firms and companies (56)

ALTA Partners profile · All research reports